BioSpace News Archive

Fact.MR – A Market Research and Competitive Intelligence Provider: As per latest Fact.MR analysis, the intraoperative MRI equipment market is projected to accelerate at a healthy 7.5% CAGR during the forecast period of 2017 to 2026.

Fact.MR – A Market Research and Competitive Intelligence Provider: Sales in the global back table and cart covers market are slated to grow at above 2.9% CAGR through 2027, opines Fact.MR.

The bio decontamination market has been anticipated to experience innumerable growth opportunities in the upcoming years.

Lysogene, a phase 3 gene therapy platform Company targeting central nervous system diseases, announced that the Medicines and Healthcare products Regulatory Agency has awarded LYS-GM101 investigational gene therapy an ‘Innovation Passport’ for the treatment of GM1 gangliosidosis under the United Kingdom’s Innovative Licensing and Access Pathway.

Targovax ASA, a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, announces mOS of 25.0 months for treatment with ONCOS-102 in combination with Standard of Care chemotherapy in malignant pleural mesothelioma in the subgroup of patients receiving therapy in the first-line setting.

BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announces that the company will be moved to the Mid Cap segment on Nasdaq Stockholm from January 3, 2022.

Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the 40th Annual J.P. Morgan Healthcare Virtual Conference on Monday, January 10, 2022 at 2:15 p.m. ET.

Arrowhead Pharmaceuticals, Inc. announced that it has completed a transaction to purchase 13 acres of land in the Verona Technology Park in Verona, WI, which is planned to be the site of an approximately 140,000 square foot drug manufacturing facility and an approximately 115,000 square foot laboratory and office facility to support process development and analytical activities.

Helsinn Group (Helsinn), and Xediton Pharmaceuticals Inc. (Xediton), announced today the signing of an exclusive license and distribution agreement in Canada for TRUSELTIQ™.

Achilles Therapeutics plc announced that the Company has been added to the NASDAQ Biotech Index, effective prior to market open, Monday, December 20, 2021.